Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

together with GSK and the PATH Malaria Vaccine Initiative (MVI), with grant funding from the Bill & Melinda Gates Foundation to MVI.

GlaxoSmithKline’s experimental malaria vaccine, RTS,S, has proved only 30% effective when administered to babies, as part of Africa’s largest ever clinical trial. There is a lot of pressure on ...

malaria, and others. In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily. Each year ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

EMVI = European malaria vaccine initiative; GLURP = Glutamate-rich protein; GSK = GlaxoSmithKline; LSA = Liver-stage antigen; LSP = Long-synthetic peptide; ME-TRAP = Multiepitope-thrombospondin ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ...

Expert Rev Vaccines. 2008;7(2):223-240. ME-TRAP Oxford University, MVI, Wellcome Trust Multiepitope string expressed in fowlpox and MVA Liver stage IIb CS + LSA1 epitope in attenuated viruses ...

The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...